Combining anti-PD-1 antibodies with Mn²⁺-drug coordinated multifunctional nanoparticles for enhanced cancer therapy

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Therapy

Background:

• Immune checkpoint blockade therapy, specifically anti-PD1 antibodies, shows promise in cancer treatment but has limited response rates.
• Enhancing the efficacy of anti-PD1 therapy is crucial for broader clinical application.

Purpose of the Study:

• To develop a novel nanoparticle system to augment antitumor responses of anti-PD1 therapy.
• To combine chemotherapy and photodynamic therapy within a single nanoparticle delivery platform.

Main Methods:

• Core-shell nanoparticles were synthesized using manganese ions, doxorubicin (chemotherapy), and chlorin e6 (photosensitizer).
• Nanoparticles were coated with red blood cell membranes for improved systemic delivery and stability.
• The efficacy of the nanoparticles in combination with anti-PD1 therapy was evaluated in tumor-bearing mice.

Main Results:

• The nanoparticles achieved high drug loading (up to 90 wt%) and demonstrated enhanced dispersity and stability.
• Systemic administration of coated nanoparticles significantly boosted anti-PD1 mediated antitumor responses against primary and distant tumors.
• Manganese ions within the nanoparticles provided T1-weighted magnetic resonance imaging contrast for tumor visualization.

Conclusions:

• Multimodal core-shell nanoparticles offer a promising strategy to enhance the efficacy of immune checkpoint blockade therapy.
• This approach has the potential to improve response rates in cancer patients undergoing anti-PD1 treatment.
• The developed nanoparticles also offer diagnostic capabilities through MRI contrast enhancement.